Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

TAVR linked to lower stroke risk than SAVR in patients with AS and cardiogenic shock

TAVR is also associated with a lower risk of acute kidney injury in this patient population. In-hospital mortality rates, however, are similar between the two treatment options. 

First-in-Man Experience of Robotic-Assisted Transcatheter Edge-to-Edge Repair With Pure Echo Guidance

Cardiologists and surgeons perform world’s first robot-assisted TEER

A 62-year-old women presented with severe MR and recurrent heart failure episodes. Initial data suggest the procedure was a success.

cardiologists going through the certification process

SCAI 2024 Scientific Sessions to focus on TAVR, PAD and other key trends in interventional cardiology

Interventional cardiologists from all over the world will gather for three days of educational sessions, late-breaking presentations, live cases and more. The festivities begin Thursday, May 2, in Long Beach, California. 

doctor patient discharge after heart surgery

Next-day discharge after TAVR with a self-expanding valve: 4 key takeaways

Researchers explored STS/ACR data from nearly 30,000 TAVR patients, presenting their findings in the Journal of the American Heart Association

Thumbnail

Society of Thoracic Surgeons launches new risk calculators for SAVR after TAVR, other key heart surgeries

STS risk calculators are known as a go-to resource for cardiologists, surgeons and any other healthcare providers who manage the care of heart patients. 

An 86-year-old patient is showing signs of improvement six months after receiving the world’s first implant of a new-look medical device for treating tricuspid regurgitation (TR), according to new data published in JACC: Cardiovascular Interventions.[1] The device in question, the Tricuspid Flow Optimizer, was developed by Triflo Cardiovascular, a U.S.-based biomedical company founded in 2017 by a team of structural heart specialists.

Cardiologists share update after world’s first implant of new optimizer device for tricuspid regurgitation

The Tricuspid Flow Optimizer was developed by Triflo Cardiovascular, a U.S.-based healthcare technology company founded by structural heart specialists.

old elderly couple coffee drink retired love romance man

TAVR, SAVR linked to similar QOL improvements for intermediate-risk patients after five years

TAVR was initially associated with greater benefits than surgery, but that difference faded by the end of the first year.

Lars Svensson, MD, PhD

Q&A: Cleveland Clinic’s Lars Svensson previews AATS annual meeting

Svensson, a prominent voice in cardiothoracic surgery, said he has seen a rise in enthusiasm ahead of this year's meeting.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup